ECSS
RPRX icon

Eurizon Capital SGR SpA’s Royalty Pharma RPRX Stock Holding History

Eurizon Capital SGR SpA’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
256,636
-61,775
-19% -$3.22M 0.04% 287
2026
Q1 		$15.2M Buy
+318,411
New +$13.9M 0.05% 268

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's RPRX Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Royalty Pharma (RPRX) stake by 19% in Q2 2026, selling an estimated $3.22M and leaving 256,636 shares worth $14.4M. The position accounts for 0.04% of the portfolio, ranked #287.

Eurizon Capital SGR SpA first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.2M in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Eurizon Capital SGR SpA held 256,636 shares of Royalty Pharma worth $14.4M as of Q2 2026.
  • Eurizon Capital SGR SpA sold 61,775 Royalty Pharma shares in Q2 2026, an estimated $3.22M.
  • Royalty Pharma made up 0.04% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #287 holding.
  • Eurizon Capital SGR SpA first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • Eurizon Capital SGR SpA's Royalty Pharma position peaked at $15.2M in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.